129 related articles for article (PubMed ID: 26238127)
1. [A Woman Experienced Severe Thrombocytopenia When Treated With Fluvastatin].
Potier A; Dony A; Crapsky A; Ferry O; Piney D; Dufay E
Therapie; 2015; 70(6):541-4. PubMed ID: 26238127
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.
Mukai Y; Narita M; Akiyama E; Ohashi K; Horiuchi Y; Kato Y; Toda T; Rane A; Inotsume N
Biol Pharm Bull; 2017; 40(7):1078-1085. PubMed ID: 28674251
[TBL] [Abstract][Full Text] [Related]
3. Fluvastatin versus pravastatin.
Chilton R
Am J Cardiol; 1996 Jul; 78(1):127. PubMed ID: 8712106
[No Abstract] [Full Text] [Related]
4. Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
Baek SD; Jang SJ; Park SE; Ok TJ; Leem J; Lee HS; Park SJ; Kim TH
J Korean Med Sci; 2011 Dec; 26(12):1634-7. PubMed ID: 22148003
[TBL] [Abstract][Full Text] [Related]
5. The use of fluvastatin in cardiovascular risk management.
McDonald KJ; Jardine AG
Expert Opin Pharmacother; 2008 Jun; 9(8):1407-14. PubMed ID: 18473714
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin: a review of its use in lipid disorders.
Langtry HD; Markham A
Drugs; 1999 Apr; 57(4):583-606. PubMed ID: 10235694
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin for lowering cholesterol.
Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137
[No Abstract] [Full Text] [Related]
8. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
Ayalasomayajula SP; Vaidyanathan S; Kemp C; Prasad P; Balch A; Dole WP
J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome.
Appel-Dingemanse S; Smith T; Merz M
J Clin Pharmacol; 2002 Mar; 42(3):312-8. PubMed ID: 11865968
[TBL] [Abstract][Full Text] [Related]
10. Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery.
Voûte MT; Winkel TA; Poldermans D
Expert Opin Drug Saf; 2010 Sep; 9(5):793-800. PubMed ID: 20557267
[TBL] [Abstract][Full Text] [Related]
11. [High therapeutic effect and safety of fluvastatin].
Pharm Unserer Zeit; 2003; 32(6):516-7. PubMed ID: 14639833
[No Abstract] [Full Text] [Related]
12. Interaction of clopidogrel and statins in secondary prevention after cerebral ischaemia - a randomized, double-blind, double-dummy crossover study.
Siepmann T; Heinke D; Kepplinger J; Barlinn K; Gehrisch S; Grählert X; Schwanebeck U; Reichmann H; Puetz V; Bodechtel U; Gahn G
Br J Clin Pharmacol; 2014 Nov; 78(5):1058-66. PubMed ID: 24803100
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hypercholesterolemia in kidney transplant recipients].
Fritsche L; Budde K; Neumayer HH
Dtsch Med Wochenschr; 2003 Apr; 128(16):879-81. PubMed ID: 12701034
[No Abstract] [Full Text] [Related]
14. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
Sinzinger H; Schmid P; O'Grady J
Atherosclerosis; 1999 Apr; 143(2):459-60. PubMed ID: 10217378
[No Abstract] [Full Text] [Related]
15. Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.
Meyer zu Schwabedissen HE; Siegmund W; Kroemer HK; Rollnik JD
BMC Res Notes; 2014 Oct; 7():688. PubMed ID: 25280537
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Andrus MR
Pharmacotherapy; 2004 Feb; 24(2):285-90. PubMed ID: 14998226
[TBL] [Abstract][Full Text] [Related]
17. Lack of pharmacokinetic interaction between fluvastatin and green tea in healthy volunteers.
Misaka S; Abe O; Sato H; Ono T; Shikama Y; Onoue S; Yabe H; Kimura J
Eur J Clin Pharmacol; 2018 May; 74(5):601-609. PubMed ID: 29368187
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
19. Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
Sebök B; Tóth M; Anga B; Harangi F; Schneider I
Acta Derm Venereol; 2004; 84(3):229-30. PubMed ID: 15202842
[No Abstract] [Full Text] [Related]
20. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
